Last reviewed · How we verify

F-choline intravenous injection — Competitive Intelligence Brief

F-choline intravenous injection (F-choline intravenous injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PET imaging agent. Area: Oncology.

phase 3 PET imaging agent Choline transporters Oncology Small molecule Live · refreshed every 30 min

Target snapshot

F-choline intravenous injection (F-choline intravenous injection) — Centre hospitalier de l'Université de Montréal (CHUM). F-choline is a fluorine-18 labeled choline analog used as a positron emission tomography (PET) imaging agent to visualize choline metabolism in tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
F-choline intravenous injection TARGET F-choline intravenous injection Centre hospitalier de l'Université de Montréal (CHUM) phase 3 PET imaging agent Choline transporters
F-18-Fluorocholine F-18-Fluorocholine ABX advanced biochemical compounds GmbH phase 3 PET imaging agent Choline transporters; Choline kinase
Fludeoxyglucose F 18 (FDG) Fludeoxyglucose F 18 (FDG) Teva Branded Pharmaceutical Products R&D, Inc. marketed Radiopharmaceutical; PET imaging agent Glucose transporter (GLUT1); hexokinase
Fluciclovine PET/CT Fluciclovine PET/CT OHSU Knight Cancer Institute marketed PET imaging agent Amino acid transporters (LAT1, ASCT2)
Neuraceq (florbetaben 18F) Neuraceq (florbetaben 18F) Piramal Imaging Limited marketed PET imaging agent Amyloid-beta plaques
Flotufolastat (18F) Flotufolastat (18F) Blue Earth Diagnostics marketed Folate receptor-targeted PET imaging agent Folate receptor alpha (FR-α)
18F-rhPSMA-7.3 18F-rhPSMA-7.3 Hackensack Meridian Health marketed PET imaging agent / radiopharmaceutical PSMA (prostate-specific membrane antigen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PET imaging agent class)

  1. University of California, San Francisco · 2 drugs in this class
  2. Central Hospital, Nancy, France · 1 drug in this class
  3. Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
  4. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  5. Institute for Neurodegenerative Disorders · 1 drug in this class
  6. OHSU Knight Cancer Institute · 1 drug in this class
  7. Piramal Imaging Limited · 1 drug in this class
  8. SOFIE · 1 drug in this class
  9. Universidad Central del Caribe · 1 drug in this class
  10. University of California, Irvine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). F-choline intravenous injection — Competitive Intelligence Brief. https://druglandscape.com/ci/f-choline-intravenous-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: